Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections †

Viruses

Erik De Clercq¹  Geoffrey Férir¹  Suzanne Kaptein¹ 

[1] id="aff1">Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium; E-Mails: [e-mail] (G.F.); [e-mail] (S.K

关键词: antiviral therapy;    HBV therapy;    nucleoside analogs;    viral hepatitis;   

DOI  :  10.3390/v2061279

来源: mdpi

【 摘 要 】

While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.

【 授权许可】

CC BY   
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland